Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

Liver transplantation for 23 patients with hepatocellular carcinoma

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

[Multivariate Analysis of Recurrence of Hepatocellular Carcinoma after Liver Transplantation].

Liver Transplantation for Hepatocellular Carcinoma:A Report of 60 Cases

Liver Transplantation for Patients with Hepatocellular Carcinoma after Repeat Hepatic Resection

Long-term survival after liver transplantation in hepatocellular carcinoma patients: a single-center experience

Analysis of survival and prognostic factors of liver transplantation for hepatocellular carcinoma

Human leukocyte antigen-G and prognosis of liver transplantation in patients with hepatocellular carcinoma

A Report of 28 Cases of 3-Year Follow-Up after Liver Transplantation for Advanced Hepatocellular Carcinoma.

[Liver Transplantation for Treating Hepatocellular Carcinoma].

Clinical Analysis of 21 Cases with Combined Hepatocellular and Cholangiocellular Carcinoma Treated by Liver Transplantation

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

Expanded Criterion for Hepatocellular Carcinoma in Liver Transplantation

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences

Scoring Selection Criteria Including Total Tumour Volume And Pretransplant Percentage Of Lymphocytes To Predict Recurrence Of Hepatocellular Carcinoma After Liver Transplantation

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Selection criteria of liver transplantation for hepatocellular carcinoma:a clinical evaluation and rethinking

Clinical Analysis of 67 Cases of Liver Transplantation for Hepatocellular Carcinoma

Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Recurrence Characteristics and Risk Factors.